Cervical Cancer Treatment in Shanghai – A Guide for International Patients | CMCS

Cervical Cancer Treatment in Shanghai: A Guide for International Patients

Cervical cancer is one of the most common gynecologic malignancies worldwide, yet it is also one of the most preventable and, when detected early, one of the most treatable. Shanghai's leading gynecologic oncology centers offer international patients access to the full spectrum of modern cervical cancer care — from the earliest HPV infection and precancerous lesion management through to advanced and recurrent disease — combined with world-leading expertise in fertility preservation that gives young women diagnosed with cervical cancer genuine hope of maintaining their reproductive future.

Understanding Cervical Cancer: From HPV to Invasive Disease

Virtually all cervical cancers are caused by persistent infection with high-risk human papillomavirus (HPV) types, most commonly HPV 16 and HPV 18. The progression from HPV infection to invasive cancer typically takes years to decades, passing through recognizable precancerous stages (cervical intraepithelial neoplasia, CIN) that can be detected by screening and treated before cancer develops.

The cervical disease continuum:

• HPV infection: Most infections clear spontaneously within 1–2 years. Persistent high-risk HPV infection is the necessary precursor to CIN and cervical cancer.
• CIN I (mild dysplasia): Low-grade squamous intraepithelial lesion (LSIL). Most regress spontaneously; active treatment is generally not required but monitoring is essential.
• CIN II (moderate dysplasia): High-grade squamous intraepithelial lesion (HSIL). Treatment (LEEP or conization) is recommended in most cases, particularly in women over 25.
• CIN III (severe dysplasia/carcinoma in situ): High-grade lesion with high risk of progression to invasive cancer if untreated. Treatment is always recommended.
• Microinvasive cervical cancer (Stage IA): Invasion to a depth of ≤5mm. Highly curable with surgery; fertility-sparing options available for selected patients.
• Early invasive cervical cancer (Stages IB1–IB2): Clinically visible tumor confined to the cervix. Treated with radical hysterectomy or chemoradiation; fertility-sparing surgery possible for selected IB1 cases.
• Locally advanced cervical cancer (Stages IB3–IVA): Tumor extending beyond the cervix. Standard treatment is concurrent chemoradiation with brachytherapy ± immunotherapy.
• Metastatic/recurrent cervical cancer (Stage IVB/recurrent): Systemic therapy with pembrolizumab + chemotherapy ± bevacizumab for eligible patients.

Key Molecular and Biomarker Testing

For patients with advanced or recurrent cervical cancer, the following tests guide treatment selection:

• PD-L1 (CPS score): Required for pembrolizumab eligibility in metastatic/recurrent disease (KEYNOTE-826). Also relevant for locally advanced disease (KEYNOTE-A18).
• HPV genotyping: Identifies specific high-risk HPV types; relevant for risk stratification and management of precancerous lesions.
• MSI/MMR status: MSI-H tumors are eligible for pembrolizumab monotherapy.
• Comprehensive NGS panel: May identify additional actionable alterations in recurrent/refractory disease.
• Tumor markers: SCC antigen (squamous cell carcinoma), CEA, CA-125 as appropriate for histological type.

Fertility Preservation: Shanghai's World-Leading Programs

For young women with early-stage cervical cancer who wish to preserve their fertility, Shanghai offers the most experienced and internationally validated fertility-sparing programs in the world:

Prof. Wu Xiaohua — Fudan Cancer Hospital
Leader of the world's highest-volume single center for abdominal radical trachelectomy (>500 cases). The “Fudan Standard” for fertility-sparing cervical cancer surgery is cited in NCCN guidelines. Also leads Shanghai's highest-volume ovarian cancer surgery program (>45% of city's cases).

Prof. Jiang Hua — Red House Hospital
Director of Red House Hospital with 30 years of gynecologic oncology expertise. Modified sandwich therapy achieves 85% 3-year disease-free survival in advanced cervical cancer. Fertility-sparing program: 50% pregnancy rate, 80% full-term delivery rate.

Prof. Hua Keqin — Red House Hospital
MDT-based dual oncological and reproductive assessment program. Fertility preservation success rate: 90%. Post-surgery conception rate: 63.9%.

Prof. Wang Huaying — Fudan Cancer Hospital
Pioneer of sentinel lymph node identification in early cervical cancer to minimize lymphadenectomy morbidity and preserve fertility. 3,000+ completed gynecologic cancer surgeries.

Robotic & Minimally Invasive Surgery

Prof. Liu Xiaojun — Changzheng Hospital
Performed Asia's first 3rd-generation da Vinci single-port laparoscopic gynecologic surgery. Innovated 5 new surgical techniques in robotic gynecologic oncology. Shanghai Leading Talent.

Dr. Wu Xin — Red House Hospital
Leads Fudan University's award-winning cervical cancer precision treatment team. Research in AI diagnostic models and comparative open vs laparoscopic surgical outcomes.

HPV, Precancerous Lesions & Prevention

Prof. Sui Long — Red House Hospital
Contributor to ASCCP guidelines. Led development of China's national cervical cancer screening guidelines and 20 clinical consensus documents. Director of Cervicology.

Prof. Qiu Lihua — Renji Hospital
Pioneered photodynamic therapy (PDT) for HPV infection and CIN in China. PDT success rate: 85–95%. Developed China's national cervical cancer screening protocol for pregnant women.

Dr. Li Yanyun — Fudan Cancer Hospital
20,000+ hysteroscopy and LEEP procedures in 5 years. Pioneer of integrated HPV management across the lower genital tract: cervix, vulva, and anus.

Prof. Li Fang — Oriental Hospital
National leader in cervical disease prevention and treatment. Comprehensive expertise from CIN through invasive cancer, including minimally invasive and open surgery. Shanghai Medical Science and Technology Progress Award winner.

How to Choose: Matching Your Needs to the Right Specialist

For fertility preservation (early-stage patients): Prof. Wu Xiaohua (Fudan Cancer Hospital) and Prof. Jiang Hua / Prof. Hua Keqin (Red House Hospital) have the most extensive fertility-sparing surgery experience. Prof. Wang Huaying's sentinel lymph node program minimizes lymphadenectomy morbidity for fertility-conscious patients.

For robotic or minimally invasive surgery: Prof. Liu Xiaojun (Changzheng Hospital) is Asia's pioneer in 3rd-generation da Vinci single-port gynecologic surgery. Dr. Wu Xin (Red House Hospital) provides evidence-based guidance on open vs laparoscopic surgical selection.

For precancerous lesions or HPV infection: Prof. Sui Long (Red House Hospital) for expert colposcopy and guideline-level diagnostic precision. Prof. Qiu Lihua (Renji Hospital) for photodynamic therapy as a tissue-sparing alternative to LEEP. Dr. Li Yanyun (Fudan Cancer Hospital) for high-volume LEEP and integrated lower genital tract HPV management.

For advanced or recurrent cervical cancer: Prof. Wu Xiaohua's multidisciplinary team and Prof. Jiang Hua's sandwich therapy program offer the most comprehensive options for locally advanced and recurrent disease.

Important note: Specialist clinic schedules and availability may change. CMCS confirms current availability and appointment logistics before any travel is arranged. We strongly recommend confirming appointment details through official hospital channels before travel.

What to Prepare Before Your Shanghai Consultation

• Pathology report with histological type (squamous, adenocarcinoma, adenosquamous, other), grade, and LVSI status
• HPV typing results with specific genotypes if available
• Cervical cytology (Pap smear/ThinPrep/LBC) reports
• Colposcopy report and biopsy histology if performed
• MRI pelvis with contrast — essential for staging and surgical planning
• CT chest/abdomen/pelvis for invasive cancer staging
• PET-CT if available — for lymph node and distant metastasis assessment
• PD-L1 (CPS) testing for advanced/recurrent disease
• Tumor markers: SCC antigen, CEA, CA-125 as appropriate
• Prior treatment summary: all surgery, radiation, chemotherapy, and immunotherapy received
• Reproductive history and fertility intentions (for fertility-sparing consultations)

How CMCS Coordinates Cervical Cancer Care in Shanghai

China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For cervical cancer patients, our coordination includes:

• Case triage to the most appropriate specialist based on stage, fertility intentions, and specific needs
• Medical record translation (English, Arabic, French, Russian, and other languages)
• Remote pre-consultation case review before travel commitment
• Appointment scheduling across surgical, oncological, and colposcopy teams
• On-site interpretation during all consultations and procedures
• MDT submission for complex cases requiring multidisciplinary review
• Post-consultation summary and ongoing follow-up coordination
• Liaison with the patient's home gynecologist or oncologist for continuity of care

Contact CMCS to Begin Your Consultation

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com

CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.